Loading...
Loading...
Synta Pharmaceuticals Corp.
SNTA announced today that the U.S. Food
and Drug Administration (FDA) has granted Fast Track designation to the
investigation of ganetespib, the Company's lead Hsp90 inhibitor drug
candidate, to improve overall survival when administered in combination with
docetaxel for the treatment of patients with metastatic non-small cell lung
adenocarcinoma who have progressed following one prior chemotherapy regimen.
FDA's Fast Track Drug Development Program is designed to facilitate the
clinical development and expedite the review of drugs that are intended to
treat serious medical conditions and that demonstrate the potential to fill
unmet medical needs.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in